Transgene is designing and developing next-generation immunotherapeutics against cancer
TG4050
First positive data
from Phase I clinical trials
–> article annonceHome
Innovative technologies
Push the boundaries of immunotherapy
Transgene combines cutting-edge technologies, a multidisciplinary team and a prestigious international network.
Discover our two therapeutic approaches
Discover our technologies
One patient, one cancer, one vaccine
With myvac®, Transgene enters the field of individualized immunotherapies with a unique virus-based immunotherapy platform.
myvac® video Discover myvac®
A new generation of products
These innovative multifunctional OVs are able to modulate the tumor micro-environment to better attack cancer.
Discover invir.IO™
TG4001
A therapeutic vaccine in Phase II
TG4001 targets HPV-induced anogenital cancers.
More information
Transgene presents data confirming the potential of oncolytic virus TG6002 administered intravenously 
Transgene in a nutshell
ESMO 2021
Donwload Press release (PDF)
TG6002 en images
–> article Home actus
Press releases
- June 28, 2022 - Transgene and BioInvent announce clinical trial collaboration and supply agreement with MSD to evaluate BT-001 in combination with KEYTRUDA®
- June 27, 2022 - Transgene and BioInvent announce positive progress for BT-001
- June 6, 2022 - Transgene Presented Additional Phase I Data with TG4050 (myvac® platform) at ASCO 2022
- May 27, 2022 - Transgene to Present Updated Positive Preliminary Data from the Phase I Clinical Trials with TG4050 (myvac® platform) at ASCO 2022
Last publications
- April 12, 2022 - Phase I trials of personalized cancer vaccine TG4050 in surgically treated high-risk head and neck squamous cell carcinoma (HNSCC) and relapsing ovarian cancer (OvC) patients
- November 9, 2021 - Vectorized Treg-depleting αCTLA-4 elicits antigen cross-presentation and CD8+ T cell immunity to reject “cold” tumors
- September 23, 2021 - Bioavailability and activity of oncolytic virus TG6002 after intravenous administration in patients with advanced gastrointestinal carcinomas
- November 9, 2020 - BT-001, an oncolytic vaccinia virus armed with a Treg-depleting human recombinant anti-CTLA4 antibody and GM-CSF to target the tumor microenvironment
Latest webcasts
- December 15, 2021 - License Option Exercise by AstraZeneca for an Oncolytic Virus Generated by Invir.IO™ Platform
- November 23, 2021 - TG4050, First positive clinical data from Phase I clinical trials
- September 22, 2021 - Half-Year results 2021 & Business Update
